Primary biliary cholangitis, or primary biliary cirrhosis, is a chronic and serious condition. When diagnosed, people with ...

Primary biliary cholangitis is a disease affecting the bile made by your liver. Here’s what to know about the causes, symptoms, treatment, and outlook.

GSK plc GSK announced that the European Medicines Agency has accepted its marketing authorization application (MAA) seeking ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

Primary biliary cholangitis, or PBC, can cause damage to the bile ducts and liver. There is currently no cure for the disease. Learn more here.

The global primary biliary cholangitis market reached a value of nearly $979.47 million in 2024, having grown at a compound annual growth rate (CAGR) of 5.96% since 2019.

A primary biliary cholangitis (PBC) diagnosis can be life-changing. For many, it’s an emotional journey filled with questions, uncertainties and a need to redefine what life looks like with a ...

EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

The Impact of Primary Biliary Cholangitis (PBC): A Rare Autoimmune Disease. By Published October 9, 2024 2:01 am October 9, 2024 ...

Optimism on Wall Street proved wise and shares of Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) rose accordingly to close June 17 at $33, up $7.08, or 27.3%, as the firm disclosed interim results from two ...